Alle Storys
Folgen
Keine Story von Grünenthal GmbH mehr verpassen.

Grünenthal GmbH

Supporting innovative pain research
EFIC-Grunenthal Grant 2009 awarded to five young scientists

Aachen, Germany (ots)

The European Federation of Chapters of the
International Association for the Study of pain (EFIC) and the 
pharmaceutical company Grunenthal awarded the EFIC-Grunenthal Grant 
to five young European scientists. The grant will provide financial 
support for their future projects in innovative, exploratory clinical
and human experimental pain research. This year's projects will 
investigate factors contributing to the development of neuropathic 
pain, the role of the hormone oxytocin in placebo analgesia and 
aspects of pain in children and newborns. Grunenthal donates a total 
of EUR 100,000 for the grant which will be divided between the five 
winners.
"We are glad that we have once again received many interesting 
research proposals from young pain researchers across Europe," said 
Professor Giustino Varrassi, President of EFIC. "As we have seen with
previous research supported by the EFIC-Grunenthal Grant, the five 
projects we have chosen this year will contribute valuable insights 
and help the medical community achieve a better understanding of 
pain. Pain is a condition affecting the everyday lives of millions of
people worldwide and also poses a huge economic burden for societies.
Understanding the mechanisms of pain is crucial to improving 
treatment in pain patients."
Winners and Projects 2009
The decision on the winners was entirely made by the EFIC 
Sub-Committee on Research, which decided to support the following 
five young researchers with EUR  20,000 each:
Luana Colloca (Italy): Oxytocin and placebo effect
Luana Colloca from the University of Turin will receive funding 
for her research on placebo effect and the role of oxytocin as a 
biochemical mediator of placebo analgesia.
Elspeth Hutton (UK): Neuroimmune cutaneous interactions in the    
genesis of chronic neuropathic pain
Elspeth Hutton from the MRC Centre for Neuromuscular Diseases, 
London is being recognised for her research on the role of skin 
neuroimmune interactions in the genesis of chronic neuropathic pain.
Rebeccah Slater (UK): Measuring pain in the human infant brain
Rebeccah Slater from University College London is focusing on 
measuring pain in the deeper structures of human infant brain and 
investigates how the infant brain is activated by noxious 
stimulation.
Tine Vervoort (Belgium): Pain demands the attention of others:    
Parental detection, interpretation and responses to their child's    
pain
Tine Vervoort from Ghent University will investigate determinants 
of parental attention to and interpretation of their child's pain and
how this influences their behaviour.
Gunnar Wasner (Germany): Role of nociceptive afferents in    
neuropathic pain
Gunnar Wasner from the University of Kiel will focus on whether 
lesions in different afferent nociceptors might influence the 
development of neuropathic pain.
"At Grunenthal we know that it is all about innovative ideas and 
the passion to move forward. With our long-term experience in pain 
therapy, we are dedicated to being a leading company in terms of 
developing new therapeutic agents in pain treatment," explained 
Wolfgang Becker, Member of the Executive Board of Grunenthal GmbH. 
"With the EFIC-Grunenthal Grant we hope to drive innovative ideas and
encourage passionate researchers who are working for a better 
understanding of pain. We wish the winners all the best for their 
projects and are looking forward to learning more about the results 
of their research."
Further information on the EFIC-Grunenthal Grant, including this 
year's winners and projects, is available at www.e-g-g.info . A 
digital press kit including photos from the award ceremony is 
accessible online at: www.grunenthal.com/press
About EFIC
The European Federation of IASP(R) Chapters (EFIC(R)) is a 
multidisciplinary professional organisation in the field of pain 
science and medicine, made up of over 34 European Chapters of 
IASP(R). Established in 1993, by Professor Ulf Lindblom, EFIC's 
constituent chapters represent close to 20,000 scientists, 
physicians, nurses, physiotherapists, psychologists and other 
healthcare professionals across Europe, who study pain and treat 
patients in pain. www.efic.org
About Grunenthal
Grunenthal is passionate about being the preferred global partner 
in pain management for patients, health care professionals and 
payors. The corporation drives innovation to expand European market 
leadership in moderate to severe pain. Grunenthal is an independent, 
family-owned German corporation with companies in 34 countries all 
over the world. Founded in 1946, the corporation employs 2,000 people
in Germany and 5,200 worldwide. In 2008, Grunenthal achieved revenues
of about 864 million Euros. More information: www.grunenthal.com
Current press materials are available in the press section at: 
www.grunenthal.com
Contacts:
Grunenthal GmbH 
Dr Nicole Foellmer 
Phone:  +49/241-569-2858 
Fax:    +49/241-569-52858 
E-Mail:  nicole.foellmer@grunenthal.com
Hering Schuppener Healthcare 
Bjoern Haertel 
Phone:  +49/40-36-80-75-21 
Fax:    +49/40-36-80-75-99 
E-Mail:  bhaertel@hs-healthcare.de

Weitere Storys: Grünenthal GmbH
Weitere Storys: Grünenthal GmbH
  • 11.10.2007 – 14:05

    Micropill Belara® improves impure skin

    Paris (ots) - At this year's 7th congress of the European Society of Gynaecology (Paris, 10-14 October 2007), the German pharmaceutical company Grunenthal GmbH presents the latest study results for its oral contraceptive Belara®. As the first of its kind the dermatological CEFIS-Study* of the University of Hamburg shows an impressive cosmetic improvement of impured skin due to the anti-androgenic properties of ...